Case Report

Wide Resection and Iliac Crest Arthrodesis for Multiply Recurrent Giant Cell Tumor of First Metatarsal

Andrew Golz, Michael Murphy, Lukas Nystrom, and Adam Schiff

1Loyola University Medical Center, 2160 S 1st Ave. Maywood, IL 60153, USA
2Cleveland Clinic, 9500 Euclid Ave. Cleveland, OH 44195, USA

Correspondence should be addressed to Michael Murphy; mmurphy12@luc.edu

Received 22 August 2018; Revised 31 October 2018; Accepted 25 November 2018; Published 3 December 2018

1. Introduction

Giant cell tumor of bone (GCTB) is a benign, aggressive neoplasm with metastatic and high local recurrence potential. Histologically, these lesions consist of cytologically benign mononuclear round, ovoid, or spindle cells mixed with evenly distributed osteoclast-like multinucleated giant cells. GCTB makes up 20% of benign bone tumors and 5% of all primary bone tumors [1]. This condition most commonly occurs in patients 30–50 years old, with 90% of the cases arising in patients after the second decade of life and only 2–7.5% of the cohort in patients with open physes [2–4]. Some series show slight female predilection [1].

GCTB most commonly occurs in the long bones, namely the distal femur, proximal tibia, and distal radius, altogether accounting for 50% of the cases [2]. In the foot, the most commonly involved bone is the talus, followed by the calcaneus, with rare occurrence in the metatarsals [5]. Giant cell tumors (GCT) of small bones are reportedly more aggressive than GCT of long bones and can have high recurrence rates [6].

In terms of treatment, nonoperative methods are being used more frequently, including the use of denosumab, which is approved by the U.S. Food and Drug Administration for use in unresectable GCTB. However, operative treatment is most commonly pursued, and first-line treatment is intraleisional curettage. Local adjuvants are often added to decrease the recurrence rate, and multiple studies suggest its increased efficacy compared to curettage alone [6–8]. En bloc excision and even amputation can be used for recurrent or recalcitrant cases. Regardless of treatment, the rate of recurrence of GCT of small bones trends toward the higher end of the ranges for all bones: 27–65% after curettage alone, 12–34% after curettage with adjuvants, and 0–12% after complete resection [2, 6, 8–11].

There are no detailed reports in the literature regarding the management of multiply recurrent giant cell tumor of the first metatarsal. We report a case of a second recurrence of giant cell tumor of the first metatarsal in a female who was treated successfully with wide resection and iliac crest arthrodesis. The following technique shows promise for addressing this difficult clinical problem.

2. Case Report

A 22-year-old woman with a known history of giant cell tumor of the left first metatarsal was evaluated for worsening left medial midfoot pain. She had previously undergone...
curettage and polymethylmethacrylate (PMMA) cementation of a biopsy-proven giant cell tumor of the first metatarsal two and a half years prior at a different institution. Six months following the index surgery, she had a recurrence treated with repeat curettage, liquid nitrogen local adjuvant, and placement of bone substitute graft. After the second procedure, she was ambulatory, but occasionally used a boot for comfort and avoided high-impact activities. Physical examination demonstrated a prominent first metatarsal base and a well-healed dorsal incision. She exhibited tenderness to palpation throughout the area of the scar.

Radiographs of the left foot showed an expansile, radiolucent lesion of the first metatarsal base surrounding the known cement implantation of the first metatarsal (Figure 1). Magnetic resonance imaging showed a large soft-tissue mass surrounding the first metatarsal circumferentially and abutting the second metatarsal (Figure 2). There was high T2 signal with no T1 signal changes at the base of the second metatarsal. Computed tomography (CT) scan demonstrated an expansile lucency at the proximal aspect of the first metatarsal base toward the dorsal lateral side (Figure 3). There were some areas of cortical breach, and the bone was expanded and abutting the base of the second metatarsal. There was no evidence of direct extension into the second metatarsal or areas of osteolysis within the second metatarsal base. She was diagnosed with a second recurrence of giant cell tumor of bone of the first metatarsal base. As the tumor was recurrent, with destruction of the articular surface and little residual bone of the first metatarsal base, a wide resection of the tumor was recommended.

2.1. Surgical Technique. The procedure began by harvesting iliac crest bone graft (5 cm in length, 2 cm in depth). The prior dorsal incision was extended along the entire first metatarsal and proximally across the tarsometatarsal (TMT) joint. A wide resection was performed by disarticulating the TMT joint, maintaining periosteal coverage surrounding the metatarsal, and osteotomizing the metatarsal about 4.5 cm from the TMT joint. The damaged cuneiform articular surface (from articulation with cement) was resected with a wafer osteotomy. The resection bed was treated with adjuvant thermal necrosis. Margins were extended further with 10% hydrogen peroxide. The first toe was held in appropriate length and rotation and pinned to the second metatarsal. The iliac crest graft was fashioned to fit appropriately, contouring the angles for an appropriate junction. The graft was secured with an anatomic plate and screw construct (Figures 4 and 5).

2.2. Postoperative Course and Follow-Up. Nonweight bearing was maintained until the three month postoperative visit, at which time she began weight bearing as tolerated through the heel and 50% weight bearing through the forefoot with a removable boot. Four months following her operation, she was advanced to full weight bearing as tolerated in the boot. Five months after surgery, she began weight bearing as tolerated in a regular shoe and nonimpact exercises. Nine months after surgery, plain radiographs and CT demonstrated osseous bridging at both the proximal and distal graft sites with no signs of tumor recurrence (Figure 6). At one year following surgery, she denied pain in the left foot and was able to complete all activities of daily living without difficulty. Eighteen months following surgery, the patient had no left foot pain, was exercising without difficulty, and there was no radiographic evidence of recurrence. The patient was informed that data concerning the case would be submitted for publication, and she agreed.

3. Discussion

In this case, we describe surgical resection and reconstruction of a second recurrence of giant cell tumor of the first metatarsal. Nonsurgical risk factors for recurrence are controversial, with some authors discounting all risk factors [12, 13]. Others endorse younger age; location in the distal radius, proximal tibia, and proximal femur; increasing Campanacci grade; larger soft-tissue mass; and bone envelope destruction to have higher rates of recurrence [14]. In addition, recurrence is related to the intervention chosen. Although nonoperative methods are being utilized more frequently, operative intervention is most commonly pursued and includes curettage with or without bone grafting, curettage with local adjuvants, en bloc resection, and amputation. Standard or
first-line treatment of long bone GCT is intralesional curettage. A recent systematic review of GCTB in the small bones of hands and feet reported a 72% recurrence rate with curettage alone [6].

Local adjuvants are often added to decrease the recurrence rate and include phenol, liquid nitrogen (cryosurgery), hydrogen peroxide, ethanol, argon, high-speed burr, and polymethylmethacrylate. This patient was initially treated with curettage and PMMA cementation. Multiple studies suggest that this method is more effective in decreasing the chance of recurrence compared to curettage alone, with rates ranging from 14.3% to 22% [7, 8, 11]. This may be due to thermal necrosis of superficial tumor cells at the time of cementation [15].

Bone grafting is often employed to fill the resultant bony defect because there is no risk of disease transmission, there is no donor-site morbidity, and it provides sufficient mechanical support for early mobilization and rehabilitation. However, this method does not appear to drastically decrease the rate of recurrence. One study exhibited 45% recurrence in 677 patients treated with this method [16]. Since this patient had already undergone previous curettage, it was reasonable that the outside surgeon chose to use bone substitute graft in her second procedure, as it can fill defects and has osteoconductive qualities.

Multiple studies have also investigated systemic medical therapy designed to stabilize local and metastatic disease. Bisphosphonates inhibit GCTB-associated osteoclast resorption and promote osteoclast apoptosis. Some studies have demonstrated stabilization of disease with bisphosphonate-aided treatments, although there is heterogeneity in the regimens and specific medications utilized [17, 18]. Denosumab, a RANKL inhibitor that inhibits osteoclast maturation, is used to treat osteoporosis and skeletal pathology secondary
to bony metastases. It is also approved by the U.S. Food and Drug Administration for use in unresectable GCTB. A phase two study of denosumab with patients with recurrent or unresectable GCTB demonstrated a favorable response in 86% of patients, and interim analysis of another study demonstrated 96% of patients without disease progression at 13-month follow-up [19, 20]. While these results are encouraging, further studies are needed to demonstrate the safety and long-term efficacy of systemic therapy.

Two years after the first recurrence, the patient presented to our institution with a second recurrence. En bloc excision is often used for recurrent or recalcitrant cases, such as the one presented in this report. However, there are conflicting views, and many authors advocate utilizing curettage with adjuvants even for multiply recurrent tumors to preserve the native joint [8, 12, 21]. In general, wide resection results in lower recurrence rates than local methods [2, 21–24]. However, when Oliveira et al. specifically investigated the small bones of hands and feet, the recurrence rate was higher following resection than curettage with adjuvants [6]. In addition, wide resection often results in reduced functional outcomes [6, 25–27]. Amputation can be performed but has both cosmetic and functional disadvantages.

In general, the chosen procedure should eradicate neoplastic tissue while preserving maximal function. Given that

Figure 4: Intraoperative imaging demonstrating a wide resection disarticulating the TMT joint, placement of the graft in an appropriate position, and plate and screw fixation.

Figure 5: Intraoperative photographs demonstrating wide resection of proximal metatarsal and reconstruction with a TMT arthrodesis plate.
this patient had only a single cortex of her metatarsal remaining, the defect was uncontained and it was felt that the lesion had a very high risk of recurrence with repeat curettage, especially in the setting of a second recurrence with previous use of multiple local adjuvants. Greater morbidity was accepted in this case to prevent local recurrence and pulmonary metastasis, which has been shown to be increased in patients with recurrent disease [28]. In addition, the surgical choice was felt to be amenable to limb-sparing surgery given that the defect was reconstructible with a structural bone graft.

Excision usually requires reconstruction; methods include arthrodesis, extensive bone grafting, and bulk or structural allografts. Multiple case reports of GCT of the first metatarsal treated with excision and reconstruction with either iliac crest or fibular graft have been reported with no signs of recurrence and resumption of normal activities at short to midterm follow-up [29, 30]. Previous studies have also examined the efficacy of excision and reconstruction following the first recurrence of GCTB in the first metatarsal. Balaji et al. reported on two cases of recurrence in adolescents, one of which underwent Boyd’s amputation. The second patient had a previous resection and unspecified reconstruction, and then underwent excision and ipsilateral fibular autograft, with return to regular activities with no signs of recurrence at 1-year follow-up [31]. Another study details the use of first metatarsal allograft for reconstruction following excision of recurrent GCT of the first metatarsal [32]. None, however, have examined treatment for multiply recurrent GCT of the first metatarsal as we have in this report. Iliac crest autograft was chosen in this case due to its established efficacy in foot and ankle arthrodesis surgery, a higher concentration of osteoprogenitor cells than grafts from the lower extremity, and relatively low donor-site pain [33–35].

In summary, nonoperative methods are being used more frequently to treat GCTB, including the use of systemic therapy such as denosumab. Operative treatment is most commonly pursued, with intralesional curettage as the appropriate first step. Local adjuvants are often added to decrease the recurrence rate, and multiple studies suggest its increased efficacy compared to curettage alone. En bloc excision and even amputation can be used for recurrent or recalcitrant cases, such as in this case. The first recurrence in small bones typically occurs before two years, although it is possible for multiple recurrences to occur years after the initial presentation [6]. This patient will require further surveillance, but at the time of this report she has achieved an excellent functional outcome with no signs of another recurrence.

Conflicts of Interest

The authors declare that they have no conflicts of interest.

References

[1] R. E. Turcotte, “Giant cell tumor of bone,” *Orthopedic Clinics of North America*, vol. 37, no. 1, pp. 35–51, 2006.

[2] M. Campanacci, N. Baldini, S. Boriani, and A. Sudanese, “Giant-cell tumor of bone,” *The Journal of Bone and Joint Surgery*, vol. 69, no. 1, pp. 106–114, 1987.
[3] C. H. Lee, I. Espinosa, K. C. Jensen et al., "Gene expression profiling identifies p63 as a diagnostic marker for giant cell tumor of the bone," *Modern Pathology*, vol. 21, no. 5, pp. 531–539, 2008.

[4] J. D. Morgan and J. L. Eady, "Giant cell tumor and the skeletally immature patient," *Journal of the Southern Orthopaedic Association*, vol. 8, no. 4, pp. 275–278, 1998.

[5] C. Yurdugul, E. Altan, M. Tonbul, and M. U. Ozbaydar, "Giant cell tumor of second and third metatarsals and a simplified surgical technique: report of two cases," *The Journal of Foot and Ankle Surgery*, vol. 50, no. 2, pp. 230–234, 2011.

[6] V. C. Oliveira, L. van der Heijden, I. C. M. van der Geest et al., "Giant cell tumours of the small bones of the hands and feet: long-term results of 30 patients and a systematic literature review," *The Bone & Joint Journal*, vol. 95-B, no. 6, pp. 838–845, 2013.

[7] C. L. Gaston, R. Bhumbra, M. Watanuki et al., "Does the addition of cement improve the rate of local recurrence after curettage of giant cell tumours in bone?," *The Journal of Bone and Joint Surgery-British Volume*, vol. 93-B, no. 12, pp. 1665–1669, 2011.

[8] K. Arbeitsgemeinschaft, W. T. Becker, J. Dohle et al., "Local recurrence of giant cell tumor of bone after intralesional treatment with and without adjuvant therapy," *The Journal of Bone and Joint Surgery-American Volume*, vol. 90, no. 5, pp. 1060–1067, 2008.

[9] M. Balke, L. Schrempfer, C. Gebert et al., "Giant cell tumor of bone: treatment and outcome of 214 cases," *Journal of Cancer Research and Clinical Oncology*, vol. 134, no. 9, pp. 969–978, 2008.

[10] C. Errani, P. Ruggieri, M. A. N. Asenjo et al., "Giant cell tumor of the extremity: a review of 349 cases from a single institution," *Cancer Treatment Reviews*, vol. 36, no. 1, pp. 1–7, 2010.

[11] A. H. Kivioja, C. Blomqvist, K. Hietaniemi et al., "Cement is recommended in intralesional surgery of giant cell tumors: a Scandinavian sarcoma group study of 294 patients followed for a median time of 5 years," *Acta Orthopaedica*, vol. 79, no. 1, pp. 86–93, 2008.

[12] F. M. Klenke, D. E. Wenger, C. Y. Inwards, P. S. Rose, and F. H. Sim, "Recurrent giant cell tumor of long bones: analysis of surgical management," *Clinical Orthopaedics and Related Research*, vol. 469, no. 4, pp. 1181–1187, 2011.

[13] M. A. Ghert, M. Rizzo, J. M. Harrelson, and S. P. Scully, "Giant-cell tumor of the appendicular skeleton," *Clinical Orthopaedics and Related Research*, vol. 400, pp. 201–210, 2002.

[14] Y. He, J. Zhang, and X. Ding, "Prognosis of local recurrence in giant cell tumour of bone: what can we do?," *La Radiologia Medica*, vol. 122, no. 7, pp. 505–519, 2017.

[15] S. Komiya and A. Inoue, "Cementation in the treatment of giant cell tumor of bone," *Archives of Orthopaedic and Trauma Surgery*, vol. 112, no. 2, pp. 51–55, 1993.

[16] G. Miller, G. Bettelli, N. Fabbri, and R. Capanna, "Curettage of giant cell tumor of bone. Introduction—material and methods," *La Chirurgia degli Organi di Movimento*, vol. 75, Supplement 1, p. 203, 1990.

[17] M. Balke, L. Campanacci, C. Gebert et al., "Bisphosphonate treatment of aggressive primary, recurrent and metastatic giant cell tumour of bone," *BMC Cancer*, vol. 10, no. 1, p. 462, 2010.

[18] L. F. Tse, K. C. Wong, S. M. Kumta, L. Huang, T. C. Chow, and J. F. Griffith, "Bisphosphonates reduce local recurrence in extremity giant cell tumor of bone: a case-control study," *Bone*, vol. 42, no. 1, pp. 68–73, 2008.

[19] D. Thomas, R. Henshaw, K. Skubitz et al., "Denosumab in patients with giant-cell tumour of bone: an open-label, phase 2 study," *The Lancet Oncology*, vol. 11, no. 3, pp. 275–280, 2010.

[20] S. Chawla, R. Henshaw, L. Seeger et al., "Safety and efficacy of denosumab for adults and skeletally mature adolescents with giant cell tumour of bone: interim analysis of an open-label, parallel-group, phase 2 study," *The Lancet Oncology*, vol. 14, no. 9, pp. 901–908, 2013.

[21] F. M. Klenke, D. E. Wenger, C. Y. Inwards, P. S. Rose, and F. H. Sim, "Giant cell tumor of bone: risk factors for recurrence," *Clinical Orthopaedics and Related Research*, vol. 469, no. 2, pp. 591–599, 2011.

[22] H. R. Dürr, M. Maier, V. Jansson, A. Baur, and H. J. Refior, "Phenol as an adjuvant for local control in the treatment of giant cell tumour of the bone," *European Journal of Surgical Oncology (EJSO)*, vol. 25, no. 6, pp. 610–618, 1999.

[23] G. S. Lausten, P. K. Jensen, T. Schiødt, and B. Lund, "Local recurrences in giant cell tumour of bone," *International Orthopaedics*, vol. 20, no. 3, pp. 172–176, 1996.

[24] D. J. McDonald, F. H. Sim, R. A. McLeod, and D. C. Dahlin, "Giant-cell tumor of bone," *The Journal of Bone and Joint Surgery*, vol. 68, no. 2, pp. 235–242, 1986.

[25] S. Gitelis, B. A. Mallin, P. Piasecki, and F. Turner, "Intralesional excision compared with en bloc resection for giant-cell tumors of bone," *The Journal of Bone and Joint Surgery*, vol. 75, no. 11, pp. 1648–1655, 1993.

[26] H. S. Liu and J. W. Wang, "Treatment of giant cell tumor of bone: a comparison of local curettage and wide resection," *Changgeng Yi Xue Za Zhi*, vol. 21, no. 1, pp. 37–43, 1998.

[27] Y. Oda, H. Miura, M. Tsuneyoshi, and Y. Iwamoto, "Giant cell tumor of bone oncological and functional results of long-term follow-up," *Japanese Journal of Clinical Oncology*, vol. 28, no. 5, pp. 323–328, 1998.

[28] C. M. Chan, Z. Adler, J. D. Reith, and C. P. Gibbs Jr., "Risk factors for pulmonary metastases from giant cell tumor of bone," *The Journal of Bone and Joint Surgery-American Volume*, vol. 97, no. 5, pp. 420–428, 2015.

[29] K. Prashant, T. D. Bhattacharyya, H. Frank, and P. Ram, "An unusual case of giant cell tumor of first metatarsal: a rare case report and review of literature," *Journal of Orthopaedic Case Reports*, vol. 6, no. 5, pp. 3–6, 2016.

[30] Y. S. Siddiqui, A. B. Sabir, M. Zahid, and Julfiquea, "Giant cell tumor of the first metatarsal," *Journal of Cancer Research and Therapeutics*, vol. 7, no. 2, pp. 208–210, 2011.

[31] G. G. Balaji, A. C. Roy, and S. V. A. Justin, "Techniques in recurrent giant cell tumour of the first metatarsal in adolescents—a rare report of 2 cases," *Foot and Ankle Surgery*, vol. 19, no. 1, pp. e1–e4, 2013.

[32] E. H. M. Wang and J. J. Arbait, "Allograft reconstruction of a large giant cell tumor of the first metatarsal: a case report," *Foot & Ankle International*, vol. 29, no. 1, pp. 97–100, 2008.

[33] J. W. Brodsky, A. J. Ptaszek, and S. G. Morris, "Salvage first MTP arthrodesis utilizing ICBG: clinical evaluation and outcome," *Foot & Ankle International*, vol. 21, no. 4, pp. 290–296, 2000.
[34] C. F. Hyer, G. C. Berlet, B. W. Bussewitz, T. Hankins, H. L. Ziegler, and T. M. Philbin, “Quantitative assessment of the yield of osteoblastic connective tissue progenitors in bone marrow aspirate from the iliac crest, tibia, and calcaneus,” *The Journal of Bone and Joint Surgery-American Volume*, vol. 95, no. 14, pp. 1312–1316, 2013.

[35] J. Baumhauer, M. S. Pinzur, R. Donahue, W. Beasley, and C. DiGiovanni, “Site selection and pain outcome after autologous bone graft harvest,” *Foot & Ankle International*, vol. 35, no. 2, pp. 104–107, 2013.